Table 1 NHL1 patient characteristics and... | American Society of Hematology

Table 1

NHL1 patient characteristics and outcomes by dose level

Patient number	CAR⁺ T-cell dose	Disease histology	Patient age (years)	KPS at HCT	Pre-HSCT disease status	Deauville score²⁴ before HSCT	Days to ANC ≥500	Best response	Disease status at data lock	Time (months) to progression or last follow-up
1-1	25 × 10⁶	DLBCL	75	90	PIF/SD	4	12	CR	CR	37.3
1-2	50 × 10⁶	DLBCL	51	90	PR	1	11	Continuing PR	Continuing PR	26.7
1-3	50 × 10⁶	DLBCL	68	90	SD	5*	10	CR	Progressed	6.7
1-4	50 × 10⁶	DLBCL	50	90	CR2	1	11	Continuing CR	Continuing CR	24.8
1-5	50 × 10⁶	MCL	69	90	CR2	1	11	Continuing CR	Continuing CR	24
1-6	100 × 10⁶	DLBCL	58	90	PR	4	11	Progressed	Progressed	1.9
1-7	100 × 10⁶	DLBCL	57	90	SD	4	12	PR	Progressed	10.4
1-8	100 × 10⁶	DLBCL	65	90	CR2	1	12	Continuing CR	Progressed	6.5

Patient number	CAR⁺ T-cell dose	Disease histology	Patient age (years)	KPS at HCT	Pre-HSCT disease status	Deauville score²⁴ before HSCT	Days to ANC ≥500	Best response	Disease status at data lock	Time (months) to progression or last follow-up
1-1	25 × 10⁶	DLBCL	75	90	PIF/SD	4	12	CR	CR	37.3
1-2	50 × 10⁶	DLBCL	51	90	PR	1	11	Continuing PR	Continuing PR	26.7
1-3	50 × 10⁶	DLBCL	68	90	SD	5*	10	CR	Progressed	6.7
1-4	50 × 10⁶	DLBCL	50	90	CR2	1	11	Continuing CR	Continuing CR	24.8
1-5	50 × 10⁶	MCL	69	90	CR2	1	11	Continuing CR	Continuing CR	24
1-6	100 × 10⁶	DLBCL	58	90	PR	4	11	Progressed	Progressed	1.9
1-7	100 × 10⁶	DLBCL	57	90	SD	4	12	PR	Progressed	10.4
1-8	100 × 10⁶	DLBCL	65	90	CR2	1	12	Continuing CR	Progressed	6.5

KPS, Karnofsky performance status

Patient had a new single subcutaneous nodule of 11 × 7 millimeters. It was ¹⁸F-fluorodeoxyglucose avid (SUV 5.0 g/mL) but was not biopsied.